Study finds that costly new antipsychotics offer few benefits over traditional drugsBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7519.717 (Published 29 September 2005) Cite this as: BMJ 2005;331:717
All rapid responses
Over the past few days there has been a heated discussion regarding
the cost effectiveness, and superiority of the two of the most widly used
classes of drugs in Psychiatry- all thanks to the series of articles in
various journals on the issue.
It all started with the results of CATIE
study by NIMH.  Quite coincidently results emerged from other studies. But
are we looking at the issue in the correct prspective before concluding
that there is not much to choose between the two class of drugs for our
patients. The first line treatments, for the majority of psychotic
illness, these days tend to be the atypical antipsychotics rather than
the older antipsychotics.Before expecting the findings from the CATIE do
we need to look at the study design in detail/ try to explore the
shortcomings in the methodology of this study. Over the years it has been
shown by various studies that the atypicals are better tolerated than the
typical neuroleptics.[3-5] They have even better effectiveness foe certain
symptim dimensions in schizophrenia like negative symptoms and cognitive
disturbances. So one needs to tke into account all these issues before
jumping on to the premature conclusions and giving the final verdict.
2. Study finds that costly new antipsychotics offer few benefits over
BMJ 2005; 331: 717
3 Atypical antipsychotic medication in the treatment of bipolar affective disorders.
Lecturer in Psychiatry, Eginition Hospital, University of Athens, Greece.
from International Society on Brain and Behaviour: 1st International Congress on Brain and Behaviour
Hyatt Regency Hotel, Thessaloniki, Greece, 20–23 November, 2003.
Annals of General Hospital Psychiatry 2003, 2(Suppl 1):S10 doi:10.1186/1475-2832-2-S1-S10http://www.annals-general-psychiatry.com/content/2/S1/S10/abstract
4 Gibson PJ, Damler R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health. 2004;7:22-35
5 New Antipsychotics, Compliance, Quality of Life, and Subjective Tolerability—Are Patients Better Off?
A George Awad, MB, BCh, FRCPC, PhD1, Lakshmi NP Voruganti, MD, FRCPC, PhD2.http://www.cpa-apc.org/Publications/Archives/CJP/2004/may/awad.asp
Competing interests: No competing interests